Newborn Screening for Fabry Disease: Current Status of Knowledge

Abstract

by Vincenza Gragnaniello,Alessandro P. Burlina,Anna Commone,Daniela Gueraldi,Andrea Puma,Elena Porcù,Maria Stornaiuolo,Chiara Cazzorla andAlberto B. Burlina
Int. J. Neonatal Screen. 2023, 9(2), 31; https://doi.org/10.3390/ijns9020031 - 1 july 2023
Cited by 8 | Viewed by 3153
Abstract
Fabry disease is an X-linked progressive lysosomal disorder, due to α-galactosidase A deficiency. Patients with a classic phenotype usually present in childhood as a multisystemic disease. Patients presenting with the later onset subtypes have cardiac, renal and neurological involvements in adulthood. Unfortunately, the diagnosis is often delayed until the organ damage is already irreversibly severe, making specific treatments less efficacious. For this reason, in the last two decades, newborn screening has been implemented to allow early diagnosis and treatment. This became possible with the application of the standard enzymology fluorometric method to dried blood spots. Then, high-throughput multiplexable assays, such as digital microfluidics and tandem mass spectrometry, were developed. Recently DNA-based methods have been applied to newborn screening in some countries. Using these methods, several newborn screening pilot studies and programs have been implemented worldwide. However, several concerns persist, and newborn screening for Fabry disease is still not universally accepted. In particular, enzyme-based methods miss a relevant number of affected females. Moreover, ethical issues are due to the large number of infants with later onset forms or variants of uncertain significance. Long term follow-up of individuals detected by newborn screening will improve our knowledge about the natural history of the disease, the phenotype prediction and the patients’ management, allowing a better evaluation of risks and benefits of the newborn screening for Fabry disease. Full article
► Show Figures
13 pages, 314 KiB
Open AccessReview